[Therapy of cerebrovascular insufficiency. A psychometric double-blind trial with a slow-release form of xantinol nicotinate (author's transl)].
Of 80 geriatric patients with cerebral insufficiency, 40 received 1000 mg of a slow-release form of xantinol nicotinate (XN) and 40 a placebo twice daily for 12 weeks. According to the co-variant analytical evaluation of the placebo/verum differences with the initial values as covariable after 12 weeks' application, XN influenced most of the investigated geriatric complaints favorably and improved the general intellectual capacity. Central activation and concentration are already improved after 6 weeks' treatment with XN.
D000368:Aged; D001288:Attention / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005853:Geriatrics; D006801:Humans; D007398:Interpersonal Relations; D008297:Male; D008568:Memory / Q000187:drug effects; D013806:Theophylline / Q000031:analogs & derivatives*; D014971:Xanthinol Niacinate / Q000627:therapeutic use*
D014971:Xanthinol Niacinate; D013806:Theophylline
Zur Therapie der zerebrovaskulären Insuffizienz. Eine psychometrische Doppelblindstudie mit Xantinol-nicotinat.